Home » Stocks » VYNE

VYNE Therapeutics, Inc. (VYNE)

Stock Price: $1.84 USD -0.03 (-1.60%)
Updated Jan 22, 2021 2:48 PM EST - Market open
Market Cap 319.98M
Revenue (ttm) 16.71M
Net Income (ttm) -253.89M
Shares Out 167.74M
EPS (ttm) -3.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $1.84
Previous Close $1.87
Change ($) -0.03
Change (%) -1.60%
Day's Open 1.85
Day's Range 1.79 - 1.87
Day's Volume 2,033,238
52-Week Range 1.03 - 5.53

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 day ago

BRIDGEWATER, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced the execution of a contract with a major PBM for its novel ...

GlobeNewsWire - 1 month ago

Company on track to initiate the TRILOGY Phase 3 program in 2021 Company on track to initiate the TRILOGY Phase 3 program in 2021

GlobeNewsWire - 1 month ago

BRIDGEWATER, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE”), a specialty pharmaceutical company focused on developing and commercializing proprietary th...

GlobeNewsWire - 1 month ago

BRIDGEWATER, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will partici...

Seeking Alpha - 2 months ago

VYNE Therapeutics (VYNE) CEO David Domzalski on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 3 months ago

Vyne Therapeutics is executing well, successfully launching 2 differentiated dermatology products this year.

PRNewsWire - 3 months ago

BRIDGEWATER, N.J., Oct. 7, 2020 /PRNewswire/ -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today announced a coverage update for its novel ZILXI™ (minocycline) topical foa...

PRNewsWire - 3 months ago

BRIDGEWATER, N.J., Oct. 1, 2020 /PRNewswire/ -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today announced that its novel ZILXI™ (minocycline) topical foam, 1.5% will be a...

GlobeNewsWire - 3 months ago

ZILXI is the First FDA Approved Minocycline Product for the Treatment of Inflammatory Lesions of Rosacea in Adults

Seeking Alpha - 3 months ago

Since the time of my last article, Vyne's market cap has dropped from $330 million to just $285 million.

GlobeNewsWire - 3 months ago

Live webinar on October 1st to feature presentations by 3 KOLs in dermatology Live webinar on October 1st to feature presentations by 3 KOLs in dermatology

GlobeNewsWire - 4 months ago

BRIDGEWATER, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the Board of Directors of the Company appointed Mr....

GlobeNewsWire - 4 months ago

BRIDGEWATER, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will pres...

PRNewsWire - 4 months ago

BRIDGEWATER, N.J., Sept. 8, 2020 /PRNewswire/ -- VYNE Therapeutics Inc.

Seeking Alpha - 5 months ago

Menlo Therapeutics' (MNLO) CEO David Domzalski on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Menlo Therapeutics Inc. (MNLO) delivered earnings and revenue surprises of -476.19% and 472.94%, respectively, for the quarter ended June 2020.

Seeking Alpha - 6 months ago

MNLO's enterprise valuation at $1.70/share is

Seeking Alpha - 7 months ago

Menlo Therapeutics: Strong Amzeeq Launch, Recent Zilxi Approval And Positive FCD105 Results Point To Growth Ahead

The Motley Fool - 7 months ago

The pricing of the biotech's stock offering weighed on shares.

Benzinga - 7 months ago

Menlo Therapeutics Inc (NASDAQ: MNLO) shares are trading lower on Friday, after the company reported a common stock offering of 27.05 million shares at $1.85 per share.

GlobeNewsWire - 7 months ago

BRIDGEWATER, N.J., June 05, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (“Menlo”) (Nasdaq: MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietar...

GlobeNewsWire - 7 months ago

BRIDGEWATER, N.J., June 04, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (“Menlo”) (Nasdaq: MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietar...

Seeking Alpha - 7 months ago

Menlo Therapeutics: Dip In Share Price Post Zilxi Approval Presents A Good Buying Opportunity

PRNewsWire - 7 months ago

BRIDGEWATER, N.J., May 29, 2020 /PRNewswire/ -- Menlo Therapeutics Inc. (Nasdaq: MNLO) ("Menlo" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing ...

GlobeNewsWire - 7 months ago

ZILXI™ Now Approved for Inflammatory Lesions of Rosacea in Adults ZILXI™ Now Approved for Inflammatory Lesions of Rosacea in Adults

Zacks Investment Research - 7 months ago

Menlo Therapeutics (MNLO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Seeking Alpha - 8 months ago

Should The FDA Approve Menlo Therapeutics Latest Therapy Shares Should Do Well

Seeking Alpha - 8 months ago

Menlo Therapeutics' (MNLO) CEO Dave Domzalski on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Menlo Therapeutics Inc (MNLO) delivered earnings and revenue surprises of -90.00% and -20.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for ...

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor in Menlo Therapeutics Inc. (MNLO).

Zacks Investment Research - 8 months ago

Menlo (MNLO) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

GlobeNewsWire - 8 months ago

Transaction provides non-dilutive capital including $10M up-front Transaction provides non-dilutive capital including $10M up-front

InvestorPlace - 9 months ago

There could be a reason penny stocks trade for under $5, but the returns can be monstrous if there's even minor share price appreciation.

Other stocks mentioned: EVRI, GERN, MNLO, ORBC, PLUG, RMTI, SELB
GlobeNewsWire - 9 months ago

Conference call today at 8.30am EDT Conference call today at 8.30am EDT

GlobeNewsWire - 9 months ago

BRIDGEWATER, N.J., April 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing...

GlobeNewsWire - 9 months ago

BRIDGEWATER, N.J., March 24, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing...

GlobeNewsWire - 10 months ago

BRIDGEWATER, N.J., March 20, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing...

GlobeNewsWire - 10 months ago

BRIDGEWATER, N.J., March 09, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”) announced today the completion of its merger with Foamix Pharmaceutica...

Seeking Alpha - 10 months ago

Menlo Is A Good Bet Reflecting The Upcoming Catalysts

Market Watch - 10 months ago

Menlo Therapeutics Inc. shares MNLO, -11.47% slid 25% in premarket trade Wednesday, after the biopharmaceutical company said a mid-stage trial of a treatment for chronic pruritus, a form of sk...

GlobeNewsWire - 10 months ago

Menlo to Host Conference Call Today at 8:30 AM Eastern Time; Foamix’s CEO David Domzalski will be Available for Q&A Menlo to Host Conference Call Today at 8:30 AM Eastern Time; Foamix’s CEO Da...

GlobeNewsWire - 11 months ago

REDWOOD CITY, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treat...

GuruFocus - 11 months ago

Steven Cohen (Trades, Portfolio), manager of Point72 Asset Management, disclosed this week that his firm established a new holding in Menlo Therapeutics Inc.

Seeking Alpha - 1 year ago

Foamix Pharmaceuticals Ltd. (FOMX) CEO Dave Domzalski on Q3 2019 Earnings & Merger Announcement with Menlo Therapeutics Conference (Transcript)

Other stocks mentioned: FOMX, MNLO
Market Watch - 1 year ago

Shares of Menlo Therapeutics Ltd. MNLO, -9.09% was indicated down 14% in premarket trading Monday, and Foamix Pharmaceuticals Ltd. FOMX, -27.53% plunged 16%, after the company's announced a me...

Other stocks mentioned: FOMX, MNLO
GlobeNewsWire - 1 year ago

REHOVOT, Israel, BRIDGEWATER, N.J. and REDWOOD CITY, Calif., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX ) (“Foamix”) and Menlo Therapeutics Inc. (Nasdaq: MNL...

Seeking Alpha - 1 year ago

Pruritogenic responses usually evolve from chronic diseases predominantly affecting the skin and liver.

GlobeNewsWire - 1 year ago

- Pivotal results expected in March/April 2020 -

GlobeNewsWire - 1 year ago

-Management to Review Late Stage Development, NDA-readiness and Commercial Opportunity of Serlopitant-

GlobeNewsWire - 1 year ago

REDWOOD CITY, Calif., Oct. 11, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, presented results from its successful Phase 2 clinical...

About VYNE

VYNE Therapeutics, a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. It offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. The company is also developing FMX103, which is in Phase III clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and FCD105, a topical combination foam that is in Phase II clinical trials for the treatment of moder... [Read more...]

Industry
Biotechnology
IPO Date
Jan 25, 2018
CEO
David T. Domzalski
Employees
40
Stock Exchange
NASDAQ
Ticker Symbol
VYNE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for VYNE stock is "Strong Buy." The 12-month stock price forecast is 5.69, which is an increase of 209.24% from the latest price.

Price Target
$5.69
(209.24% upside)
Analyst Consensus: Strong Buy